Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice. Although rapamycin is an FDA-approved drug for select indications, a diverse set of negative side effects may preclude its wide-scale deployment as an antiaging therapy. mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo. Over the past decade, it has become clear that although genetic and pharmacological inhibition of mTORC1 extends lifespan and delays aging, inhibition of mTORC2 has negative effects on mammalian health and longevity and is responsible for many of the negative side effects of rapamycin. In this review, we discuss recent advances in understanding the molecular and physiological effects of rapamycin treatment, and we discuss how the use of alternative rapamycin treatment regimens or rapamycin analogs has the potential to mitigate the deleterious side effects of rapamycin treatment by more specifically targeting mTORC1. Although the side effects of rapamycin are still of significant concern, rapid progress is being made in realizing the revolutionary potential of rapamycin-based therapies for the treatment of diseases of aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“Wild-type mice UM-HET3 Male 20 months 14 ppm Diet — 9 (40) UM-HET3 Female 20 months 14 ppm Diet 881–895 14 (40) C57BL/6J.”
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Sestrin2 is a leucine sensor for the mTORC1 pathway
Wolfson, R. L., Chantranupong, L., Saxton, R. A., Shen, K., Scaria, S. M., Cantor, J. R., & Sabatini, D. M. (2016) · Science · doi:10.1126/science.aab2674 · Cited by 1,306
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Self-citationRibosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 2×
“Mice lacking either the mTORC1 substrate S6K1, or mice doubly heterozygous for mTOR and mLST8, show a significant increase in female lifespan (17,48).”
BackgroundInfluence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057
Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033
The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway
Chantranupong, L., Scaria, S. M., Saxton, R. A., Gygi, M. P., Shen, K., Wyant, G. A., Wang, T., Harper, J. W., Gygi, S. P., & Sabatini, D. M. (2016) · Cell · doi:10.1016/j.cell.2016.02.035 · Cited by 843
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 3×
“Over the last several years, it has instead become apparent that chronic treatment with rapamycin also inhibits mTORC2 in vivo in the majority of tissues, including liver, adipose tissue, skeletal muscle, and immune cells (17,19,62).”
BackgroundmTOR inhibition improves immune function in the elderly
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009892 · Cited by 786 · cited 2×
“Indeed, even at the lowest dosage used by Mannick and colleagues, more than 40% of participants experienced at least one treatment-related adverse event, compared with 20% of those receiving a placebo (107).”
BackgroundRegulation of mTORC1 by amino acids
Bar-Peled, L., & Sabatini, D. M. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.003 · Cited by 773
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake
Yilmaz, Ö. H., Katajisto, P., Lamming, D. W., Gültekin, Y., Bauer-Rowe, K. E., Sengupta, S., Birsoy, K., Dursun, A., Yilmaz, V. O., Selig, M., et al. (2012) · Nature · doi:10.1038/nature11163 · Cited by 753
Self-citationmTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680
SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1
Rebsamen, M., Pochini, L., Stasyk, T., de Araújo, M. E. G., Galluccio, M., Kandasamy, R. K., Snijder, B., Fauster, A., Rudashevskaya, E. L., Bruckner, M., et al. (2015) · Nature · doi:10.1038/nature14107 · Cited by 673
TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxO
Robida-Stubbs, S., Glover-Cutter, K., Lamming, D. W., Mizunuma, M., Narasimhan, S. D., Neumann-Haefelin, E., Sabatini, D. M., & Blackwell, T. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.007 · Cited by 648
Self-citationmTORC1 controls fasting-induced ketogenesis and its modulation by ageing
Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646 · cited 1×
“Inhibition of hepatic mTORC1 by liver-specific deletion of Raptor rescues an age-associated defect in ketogenesis (50), whereas constitutive activation of 4E-BP1, a substrate normally repressed by mTORC1, specifically in skeletal muscle preserves metabolic health during aging (51).”
BackgroundRapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531 · cited 1×
“Rapalogs include the FDA-approved everolimus and temsirolimus plus ridaforolimus, zotarolimus, and 32-deoxo-rapamycin (101).”
BackgroundSelf-citationHoude, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456
Rapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
Ramos, F. J., Chen, S. C., Garelick, M. G., Dai, D.-F., Liao, C.-Y., Schreiber, K. H., MacKay, V. L., An, E. H., Strong, R., Ladiges, W. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003802 · Cited by 349 · cited 1×
“5 mg/kg Oral 1×/day 5 days on/9 days off 161 35 (119) Lmna−/− MF 1 month 14 ppm Diet 46 35 (120) Lmna−/− MF 1 month 8 mg/kg IP 1x/2 days 55 56 (120) Rb1+/− Male 2 months 14 ppm Diet 369 13.”
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062459 · Cited by 226
Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice
Fang, Y., Westbrook, R., Hill, C., Boparai, R. K., Arum, O., Spong, A., Wang, F., Javors, M. A., Chen, J., Sun, L. Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.008 · Cited by 195 · cited 1×
“Although short-term studies with rapamycin in mice have largely reported metabolic dysfunction as discussed earlier, at least one longer-term study reports metabolic adaptation and improved insulin sensitivity (as assessed by insulin tolerance test) following 5 months of rapamycin administration (77).”
BackgroundArriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182 · cited 2×
“Compared with rapamycin, both everolimus and temsirolimus showed a reduced but still significant impairment of glucose and pyruvate tolerance; all three compounds had similar impacts on splenocyte number (98).”
BackgroundSelf-citationHa, C. W., & Huh, W.-K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq895 · Cited by 77
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Liu, Y., Diaz, V., Fernandez, E., Strong, R., Ye, L., Baur, J. A., Lamming, D. W., Richardson, A., & Salmon, A. B. (2014) · Aging · doi:10.18632/aging.100688 · Cited by 68 · cited 1×
“However, the negative effects of chronic rapamycin on glucose homeostasis persist for at least 2 weeks following cessation of treatment (95,96), and so a three time per week schedule—with or without a washout period—may therefore be of limited use in reducing side effects.”
BackgroundSelf-citationRapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes
Sataranatarajan, K., Ikeno, Y., Bokov, A., Feliers, D., Yalamanchili, H., Lee, H. J., Mariappan, M. M., Tabatabai-Mir, H., Diaz, V., Prasad, S., et al. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv170 · Cited by 65 · cited 1×
“5 mg/kg IP 1×/week 684 b (99) Ndufs4−/− MF <1 month 42 ppm Diet 52 29NS (124) Ndufs4−/− MF <1 month 378 ppm Diet 52 92 (124) Ndufs4−/− MF <1 month 8 mg/kg IP 1×/day 52 119 (124) Rag2−/− MF 3 months 14 ppm Diet 310 121 (125) IFN-γ−/− MF 5 months 14 ppm Diet 398 34 (125) C57BLKS/J leprdb/db Male 4 months 14 ppm Diet 349…”
Research works printed but not linked: 100
- 10.7164/antibiotics.28.721 · DOI · Paper page
- 10.1139/y77-007 · DOI · Paper page
- Dumont, 1990, Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin, J Immunol, 144, 251, 10.4049/jimmunol.144.1.251 · DOI · Paper page
- 10.7164/antibiotics.32.630 · DOI
- 10.7164/antibiotics.40.1256 · DOI · Paper page
- 10.1073/pnas.89.9.3686 · DOI · Paper page
- 10.1038/357692a0 · DOI · Paper page
- 10.1016/S1874-6047(10)27002-6 · DOI
- 10.1146/annurev-nutr-071714-034355 · DOI · Paper page
- 10.1186/2193-1801-3-735 · DOI · Paper page
- 10.1016/j.cell.2015.02.041 · DOI · Paper page
- 10.1126/science.1257132 · DOI · Paper page
- 10.1016/j.molcel.2006.03.029 · DOI · Paper page
- 10.1111/acel.12313 · DOI · Paper page
- 10.1016/0277-5379(83)90012-3 · DOI · Paper page
- 10.7164/antibiotics.37.1231 · DOI · Paper page
- 10.1126/science.1115535 · DOI · Paper page
- 10.1016/j.cmet.2009.11.010 · DOI · Paper page
- 10.1101/gad.1381406 · DOI · Paper page
- 10.1371/journal.pbio.0050261 · DOI · Paper page
- 10.1111/j.1474-9726.2011.00791.x · DOI · Paper page
- 10.1111/acel.12203 · DOI · Paper page
- 10.1111/j.1474-9726.2012.00832.x · DOI · Paper page
- Lin AL Jahrling JB Zhang W . Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. J Cereb Blood Flow Metab. 2015. doi:10.1177/0271678X15621575 · DOI · Paper page
- Bai, 2015, Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy, Pathobiol Aging Age Relat Dis, 5, 28743, 10.3402/pba.v5.28743 · DOI · Paper page
- 10.1158/2159-8290.CD-13-0929 · DOI · Paper page
- 10.1158/2159-8290.CD-13-0353 · DOI · Paper page
- 10.1093/gerona/glq178 · DOI · Paper page
- 10.1111/acel.12194 · DOI · Paper page
- Zaseck LW Miller RA Brooks SV . Rapamycin attenuates age-associated changes in tibialis anterior tendon viscoelastic properties. J Gerontol A Biol Sci Med Sci. 2016. doi:10.1093/gerona/glv307 · DOI · Paper page
- Carter CS Khamiss D Matheny M . Rapamycin versus intermittent feeding: dissociable effects on physiological and behavioral outcomes when initiated early and late in life. J Gerontol A Biol Sci Med Sci. 2015. doi:10.1093/gerona/glu238 · DOI
- Arriola Apelo SI Pumper CP Baar EL Cummings NE Lamming DW . Intermittent administration of rapamycin extends the life span of female C57BL/6J mice. J Gerontol A Biol Sci Med Sci. 2016. doi:10.1093/gerona/glw064 · DOI · Paper page
- Fan, 2015, Rapamycin preserves gut homeostasis during Drosophila aging, Oncotarget, 6, 35274, 10.18632/oncotarget.5895 · DOI · Paper page
- 10.1016/j.celrep.2013.07.030 · DOI · Paper page
- 10.1172/JCI77361 · DOI · Paper page
- 10.1210/en.2014-1690 · DOI · Paper page
- 10.1111/nyas.12122 · DOI · Paper page
- 10.1681/ASN.2007111202 · DOI · Paper page
- 10.1097/01.TP.0000056639.74982.F9 · DOI
- Sonis, 2010, Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients, Cancer, 116, 210, 10.1002/cncr.24696 · DOI · Paper page
- 10.1002/phar.1692 · doi:10.1002/phar.1692
- 10.1111/j.1365-2036.2004.01923.x · DOI · Paper page
- 10.1016/j.bbmt.2005.04.007 · DOI · Paper page
- 10.1097/TP.0b013e31824bf1f0 · DOI
- 10.1097/CAD.0000000000000207 · DOI · Paper page
- 10.1681/ASN.2005050487 · DOI · Paper page
- 10.2337/diabetes.52.11.2731 · DOI · Paper page
- 10.1073/pnas.0803047105 · DOI · Paper page
- 10.1096/fj.13-237743 · DOI · Paper page
- 10.1073/pnas.0811321106 · DOI · Paper page
- 10.2337/db09-1061 · DOI · Paper page
- 10.1038/ncomms11365 · DOI · Paper page
- 10.1128/MCB.01405-07 · DOI · Paper page
- 10.1016/j.molmet.2014.06.004 · DOI · Paper page
- 10.2337/db10-1194 · DOI · Paper page
- 10.1016/j.molmet.2014.01.014 · DOI · Paper page
- 10.1002/cne.23668 · DOI
- 10.1152/ajpendo.00110.2012 · DOI · Paper page
- 10.1084/jem.20071477 · DOI · Paper page
- Byles, 2013, The TSC-mTOR pathway regulates macrophage polarization, Nature Commun, 4, 2834, 10.1038/ncomms3834 · DOI · Paper page
- 10.4049/jimmunol.1400188 · DOI · Paper page
- 10.1371/journal.pone.0095432 · DOI · Paper page
- Covarrubias AJ Aksoylar HI Yu J . Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. eLife. 2016;5. doi:10.7554/eLife.11612 · DOI · Paper page
- 10.1371/journal.pone.0016144 · DOI · Paper page
- 10.1093/gerona/54.11.B492 · DOI · Paper page
- 10.1186/2046-2395-1-3 · DOI · Paper page
- Lamming DW Anderson RM . Metabolic Effects of Caloric Restriction. Chichester, UK: John Wiley & Sons; 2014. · DOI · Paper page
- 10.1111/acel.12256 · DOI · Paper page
- 10.1111/acel.12425 · DOI · Paper page
- Lind MI Zwoinska MK Meurling S Carlsson H Maklakov AA . Sex-specific tradeoffs with growth and fitness following life-span extension by rapamycin in an outcrossing nematode, Caenorhabditis remanei . J Gerontol A Biol Sci Med Sci. 2015. doi:10.1093/gerona/glv174 · DOI
- 10.18632/aging.100401 · DOI
- 10.18632/aging.100461 · DOI · Paper page
- 10.4161/cc.10.24.18486 · DOI · Paper page
- Scarpace PJ Matheny M Strehler KY . Rapamycin normalizes serum leptin by alleviating obesity and reducing leptin synthesis in aged rats. J Gerontol A Biol Sci Med Sci. 2015. doi:10.1093/gerona/glu230 · DOI
- 10.1007/s00109-011-0834-3 · DOI · Paper page
- 10.1067/mcp.2001.112513 · DOI
- 10.1111/acel.12211 · DOI · Paper page
- 10.1093/gerona/glt056 · DOI · Paper page
- 10.1042/CS20150149 · DOI
- 10.1016/j.clgc.2014.07.006 · DOI
- 10.1016/j.transproceed.2004.01.015 · DOI
- 10.1016/j.diabres.2015.09.014 · DOI
- 10.1634/theoncologist.2010-0222 · DOI · Paper page
- 10.1177/0300985815591082 · DOI · Paper page
- 10.1038/514546a · DOI
- 10.1016/j.bbmt.2014.06.004 · DOI
- 10.1097/00007890-199604270-00015 · DOI · Paper page
- Tran CM Mukherjee S Ye L . Rapamycin blocks induction of the thermogenic program in white adipose tissue. Diabetes. 2016. doi:10.2337/db15-0502 · DOI · Paper page
- 10.1038/nbt.3163 · DOI
- 10.1371/journal.pone.0083988 · DOI · Paper page
- 10.1038/nm1560 · DOI · Paper page
- 10.2353/ajpath.2010.091050 · DOI · Paper page
- 10.1016/j.neurobiolaging.2011.06.002 · DOI
- 10.18632/aging.100498 · DOI · Paper page
- 10.18632/aging.100496 · DOI · Paper page
- 10.18632/aging.100533 · DOI · Paper page
- 10.18632/aging.100633 · DOI · Paper page
- 10.4161/cbt.28164 · DOI · Paper page
- Johnson, 2015, Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice, Front Genet, 6, 247, 10.3389/fgene.2015.00247 · DOI · Paper page
- 10.1111/acel.12380 · DOI · Paper page
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Measuring biological aging in humans: a quest
Ferrucci, L., Gonzalez‐Freire, M., Fabbri, E., Simonsick, E., Tanaka, T., Moore, Z., Salimi, S., Sierra, F., & de Cabo, R. (2020) · Aging Cell · doi:10.1111/acel.13080 · Cited by 781
Molecular mechanisms of dietary restriction promoting health and longevity
Green, C. L., Lamming, D. W., & Fontana, L. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00411-4 · Cited by 714
Self-citationAging and age‐related diseases: from mechanisms to therapeutic strategies
Li, Z., Zhang, Z., Ren, Y., Wang, Y., Fang, J., Yue, H., Ma, S., & Guan, F. (2021) · Biogerontology · doi:10.1007/s10522-021-09910-5 · Cited by 640
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
Self-citation
Metadata
- Authors
- Arriola Apelo, S. I., & Lamming, D. W.
- Venue
- The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05-21
- Volume
- 71
- Issue
- 7
- Pages
- 841-849
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- OpenAlex
- W2395395500
- Cited by
- 239
- References
- 26
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institute on Aging
- National Institutes of Health (R00 AG041765)
- University of Wisconsin–Madison School of Medicine and Public Health
- American Diabetes Association (1-16-PMF-001)
- American Federation for Aging Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.